September 16, 2025 11:45 ET | Source: Transgene S.A. Transgene S.A.
RAPPORT SEMESTRIEL 2025
Pièce jointe
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress
